Lead Product ACP-01: Primarily for the treatment of medical conditions such as:
Ischemic Diseases
Hemostemix’s technology platform for developing autologous cell therapies has the potential to treat a broad range of vascular diseases.
We are currently developing a treatment for critical limb ischemia (“CLI”), which is considered a gateway indication for broader ischemic diseases including peripheral arterial disease and cardiovascular disease.
The economic costs of CLI and cardiovascular disease in the United States alone are over $800B annually.
